“Curing” the Untouchable Cancer – Systemic Lupus Erythematosus: Chinese Experts Take a Major Leap Forward

**”Curing” the Untouchable Cancer – Systemic Lupus Erythematosus: Chinese Experts Take a Major Leap Forward**

Lupus

#LupusTreatment #HopeForLupus #lupus #AutoimmuneDisease #ChinaHealthcare #SystemicLupusErythematosus #Erythematosus

Once hailed as a revolutionary therapy in the field of oncology, Chimeric Antigen Receptor T-cell (CAR-T) therapy is now demonstrating extraordinary potential in the treatment of Systemic Lupus Erythematosus (SLE). For this troublesome autoimmune disease that has long plagued patients and doctors alike, CAR-T therapy may be the dawn of ending this struggle.

In 2021, researchers in Germany successfully treated a 20-year-old woman with severe SLE using CAR-T therapy for the first time. While CAR-T therapy had already achieved significant success in treating hematologic malignancies, it is now opening new doors for autoimmune disease treatments. Since then, over a dozen global clinical trials have been initiated to explore CAR-T’s potential for SLE, and initial results are promising.

**How Does CAR-T Treat Lupus?**

CAR-T therapy involves extracting the patient’s T-cells, genetically modifying them to recognize and destroy harmful cells, and then reinfusing them into the body. For cancer patients, this means eliminating tumor cells; for SLE patients, it means clearing the abnormal plasma cells that produce self-antibodies, thus fundamentally curing the disease.

In China, researchers are also accelerating the application of CAR-T therapy. In June and July of 2024, two patients in Shanghai received CAR-T treatment and achieved significant results. A young girl named Qingqing and an adult woman, Ms. S, saw dramatic improvements in their symptoms and discontinued all medications related to their primary illness. Laboratory test results also showed marked improvement.

“Two months after treatment, the patients’ proteinuria disappeared, and the SLE Disease Activity Index score was 0, indicating complete remission,” said nephrologist Dr. Yin Lei. “They have returned to their normal lives.”

**Breakthroughs in Autoimmune Disease Treatment**

The success of CAR-T therapy in treating SLE is not only a boon for lupus patients but also brings new hope to millions of other autoimmune disease sufferers worldwide. Currently, about 20% of the global population is affected to varying degrees by over 100 different autoimmune diseases. The advent of CAR-T therapy could revolutionize the treatment landscape for these conditions.

Despite the promising outlook, experts remain cautious. Long-term safety and efficacy still require more research to confirm. Additionally, technical challenges such as improving the quality of T-cells after immunosuppressive therapy need to be addressed.

Nevertheless, the future looks very promising. CAR-T therapy may represent the best opportunity to overcome autoimmune diseases, including lupus.

**A Brighter Future for Lupus Patients**

Although the application of CAR-T therapy in SLE is still in its early stages, preliminary results have already brought significant hope. Future research and clinical trials will help us better understand its long-term impact and further refine the technology. For those who once faced incurable diseases, the future may no longer be so bleak.

Global pharmaceutical companies are also shifting their priorities from cancer treatment to research on autoimmune diseases. As CAR-T therapy continues to advance, more patients will benefit, bringing new hope for many.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070 

(Https://wa.me/+8613717959070)

Email: doctor.huang@globecancer.com

#CAR-Ttherapy #LupusTreatment #AutoimmuneDisease #MedicalInnovation #ChinaHealthcare #Immunotherapy #CancerTreatment #HealthBreakthrough #HopeForLupus #FutureOfMedicine

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 months ago CAR-T

Chinese CAR-T Therapy: A New Frontier in Treating Systemic Lupus Erythematosus

Chinese CAR-T Therapy: A New Frontier in Treating Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

#Lupus #LupusErythematosus #SystemicLupusErythematosus #CART #CARTTherapy #SLE

Recently, CSPC PHARMA’s CAR-T product, SYS6020, received approval for clinical trials from China’s National Medical Products Administration (NMPA). This groundbreaking development represents a significant milestone in cell therapy, especially for treating refractory active systemic lupus erythematosus (SLE). Notably, SYS6020 targets the BCMA antigen, potentially providing a novel and cost-effective treatment option for SLE patients worldwide.

**Innovative Approach and Promising Safety Profile**

SYS6020 is a pioneering mRNA-LNP-based CAR-T cell injection, marking it as the first of its kind to enter clinical trials. This innovative therapy specifically recognizes the BCMA antigen, attacking and eliminating immune cells responsible for elevated autoantibodies. This approach offers a unique, safe, and effective treatment option for SLE, distinct from traditional CAR-T therapies. Notably, SYS6020 exhibits high cell viability, a high CAR-positive rate, and reduced risks of genomic integration and cytokine release syndrome (CRS), common issues with conventional CAR-T treatments.

Preclinical studies have shown that SYS6020 effectively kills BCMA antigen-positive myeloma cells while maintaining a favorable safety profile. By employing LNP for T cell transfection, the therapy significantly reduces costs compared to using lentiviral vectors, lessening the financial burden on patients.

Lupus

**Revolutionizing Treatment for Autoimmune Diseases**

SLE, a complex chronic autoimmune disease, is characterized by the immune system attacking its own tissues. According to the “Chinese Guidelines for Diagnosis and Treatment of Lupus Nephritis,” the prevalence of SLE in China is estimated to be between 30.13 and 70.41 per 100,000 individuals, translating to 422,000 to 986,000 patients.

Traditional SLE treatments, including steroids, often come with severe side effects and long-term health risks. In contrast, biological therapies have emerged as a game-changer by modulating immune responses, reducing the immune system’s attack on the body’s tissues, and decreasing dependency on steroids. However, only three biologics—belimumab, tildrakizumab, and anifrolumab—are currently approved globally.

CAR-T therapy has shown remarkable efficacy in treating refractory SLE, providing hope in a challenging therapeutic landscape. This therapy precisely targets “rogue” B cells responsible for autoantibody production, thereby minimizing organ damage and offering a more targeted approach than traditional treatments.

**Future Prospects and Ongoing Challenges**

While CAR-T therapy presents a promising new direction for SLE treatment, its long-term efficacy and safety remain under investigation. Larger clinical trials are needed to validate its effectiveness and safety, as current studies are limited to small samples.

Additionally, the potential long-term risks of CAR-T therapy, such as increased susceptibility to infections or malignancies, require thorough exploration. Despite these uncertainties, the active involvement of multiple domestic and international cell therapy companies underscores the global commitment to advancing CAR-T therapies for autoimmune diseases.

In summary, CAR-T therapy for SLE holds immense potential, with clinical trials offering hope for a safer and more effective treatment alternative. Continued research and positive trial outcomes could establish CAR-T as a viable therapeutic option for SLE patients, revolutionizing their treatment landscape.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com

#CAR_Therapy #SLETreatment #AutoimmuneInnovation #MedicalBreakthrough #LupusAwareness